Understanding how ketamine affects dissociation in epilepsy patients
Understanding Ketamine's Dissociative Effects in Epilepsy (KD Study)
This study is testing how ketamine affects brain activity and dissociation symptoms in people with epilepsy.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Stanford University Academic / other |
| Locations | 1 site (Palo Alto, California) |
| Trial ID | NCT04861051 on ClinicalTrials.gov |
What this trial studies
This research aims to investigate the effects of ketamine on brain activity in patients with epilepsy, specifically focusing on the dissociative symptoms that may arise. By utilizing stereoEEG, the study will record and analyze the brain's response to ketamine administration. The findings could provide insights into the mechanisms of dissociation and its relationship with epilepsy. This is a Phase 1 interventional study, indicating an early exploration of ketamine's effects in this context.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who are currently being monitored in the Stanford Epilepsy Monitoring Unit.
Not a fit: Patients with a history of psychotic or bipolar disorders, those unable to communicate in English, pregnant or nursing females, and individuals with prior adverse reactions to ketamine may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of dissociative symptoms in epilepsy, potentially leading to improved treatment strategies.
How similar studies have performed: While the specific approach of using ketamine to study dissociation in epilepsy is novel, there have been other studies exploring ketamine's effects in different contexts, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient in Stanford Epilepsy Monitoring Unit * Age \>18 years old. Exclusion Criteria: * Lifetime psychotic or bipolar disorder * Inability to speak, read or understand English * Pregnant or nursing females * Prior adverse ketamine response
Where this trial is running
Palo Alto, California
- Stanford University School of Medicine — Palo Alto, California, United States (Recruiting)
Study contacts
- Principal investigator: Karl Deisseroth, MD, PhD — Stanford University
- Study coordinator: Arjay Cordero
- Email: arjayc@stanford.edu
- Phone: 650-580-9000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.